PTPRC and neoplasm: Although no significant difference was observed in the expression levels of H-2Kk on tumor cells (CD45−, SSChigh) between the anti-PD-L1 antibody treatment and the control treatment groups, significantly higher expression levels were observed in the anti-PD-L1 antibody treatment combined with anti-VEGF antibody group compared with the anti-VEGF antibody treatment alone group (Fig. 6A and B).